Jak Knowles (L) and Dirk Nagorsen (Affini-T)

'Go quick­ly': Am­gen R&D vet Dirk Nagors­en jumps to a start­up with big plans for TCRs

You can call it the sum­mer of in­cep­tion at Affi­ni-T Ther­a­peu­tics, the TCR up­start out of the Fred Hutch.

Born with a trio of dis­tin­guished sci­en­tif­ic god­fa­thers, in­clud­ing Phil Green­berg. Backed by a pair of deep-pock­et in­vestors at Vi­da Ven­tures and Leaps by Bay­er, won over by Affi­ni-T’s swing-for-the-bleach­ers style. It’s even al­ready done a high-pro­file col­lab­o­ra­tion with a new gene-edit­ing biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.